*Not available for sale in all countries. Please check with your local distributor for availability in your country.
Iridex provides office-based laser solutions for your retina practice. With the patented Fovea-friendly™ MicroPulse® laser technology there is a treatment option for the most common retinal diseases.
Iridex offers high quality laser systems, EndoProbe® handpieces, and a portfolio of vitreoretinal consumables for precision surgery in the hospital and ASC.
Iridex laser systems provide traditional, MicroPulse, and transscleral laser solutions for the management of glaucoma.
Iridex products offer the versatility of traditional, MicroPulse, and transscleral laser options for the treatment of both glaucoma and retinal diseases.
May 31, 2024: Iridex to Showcase Advancements in Glaucoma Laser Solutions at the 16th European Glaucoma Society (EGS) Congress in Dublin, June 1-4, 2024
February 6, 2024: Iridex Corporation Receives European Patent on MicroPulse Technology
January 25, 2024: Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
January 12, 2024: Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
December 28, 2023: Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation
June 19, 2023: Iridex Launches Next Gen PASCAL® Laser with MicroPulse® in Full U.S. Market
April 27, 2023: Iridex to Report First Quarter Financial Results on May 11, 2023
March 9, 2023: Iridex Reports Fourth Quarter and Full Year 2022 Financial Results
March 7, 2023: Iridex to Present at the 35th Annual Roth Conference
March 2, 2023: Iridex Introduces New Research and Showcases Five Events at the AGS Meeting
February 23, 2023: Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
January 10, 2023: Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022